Lannett announced that the FDA has completed its review of the Investigational New Drug Application for biosimilar insulin glargine. Lannett plans to complete the clinical trials by early 2023, with a potential launch in early 2024.
Permit Required: Full Court Denies Access to Costs Appeal in Carpark Patent Saga
Vehicle Monitoring Systems Pty Limited v SARB Management Group Pty Ltd trading as Database Consultants Australia (Costs) [2024] FCAFC 155 ...